#SFHS2608455VNotice on Prices of Pharmaceutical Specialties Published Pursuant to Article L. 162-16-6 of the Social Security Code
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This French government notice sets the official reimbursement tariff and maximum selling price for Keytruda (pembrolizumab) 25mg/ml perfusion solution in 4ml vials. Effective 3 April 2026, both the Tarif de responsabilité HT and the Prix limite de vente HT to healthcare establishments are fixed at exactly €2,000.74 per UCD (unit). The price is established under the agreement between the Economic Committee for Health Products (CEPS) and MSD France, pursuant to Article L. 162-16-6 of the Social Security Code. It applies specifically to hospital and institutional purchases and determines the maximum amount that can be charged and reimbursed for this immunotherapy medicine.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Official hospital price for KEYTRUDA 25MG/ML PERF FL4ML (UCD 3400894197232) set at €2,000.74 HT per unit
- Tarif de responsabilité and Prix limite de vente both fixed at identical value of €2,000.74 per UCD
- Price becomes effective on 3 April 2026
+ 2 more changes with Pro
Obligations
What this law requires
Set the reimbursement tariff (Tarif de responsabilité HT) for Keytruda 25mg/ml perfusion solution 4ml vials at exactly €2,000.74 per UCD
Set the maximum selling price (Prix limite de vente HT) for Keytruda 25mg/ml perfusion solution 4ml vials to healthcare establishments at exactly €2,000.74 per UCD
Apply the established pricing for Keytruda (UCD code 34008 941 972 3 2) effective from 3 April 2026
Limit reimbursement and charging for Keytruda 25mg/ml to hospital and institutional purchases only at the fixed maximum price of €2,000.74 per UCD
Comply with the pricing agreement established between CEPS (Economic Committee for Health Products) and MSD France as specified in this notice